A systematic review of nutraceutical interventions for mitochondrial dysfunctions in ME/CFS, 2021, Marshall-Gradisnik et al

John Mac

John Mac

Senior Member (Voting Rights)
Abstract
Background
Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is a debilitating illness, characterised by persistent fatigue that is unrelieved by rest, in combination with a range of other disabling symptoms. There is no diagnostic test nor targeted treatment available for this illness. The pathomechanism also remains unclear. Mitochondrial dysfunctions have been considered a possible underlying pathology based on reported differences including structural and functional changes in ME/CFS patients compared to healthy controls. Due to the potential role that mitochondria may play in ME/CFS, mitochondrial-targeting nutraceutical interventions have been used to potentially assist in improving patient outcomes such as fatigue. The aim of this systematic review is to appraise literature assessing these nutraceuticals as a possible intervention for treating ME/CFS.

Methods
A systematic search of Pubmed, Embase, Medline (EBSCO host) and Web of Science (via Clarivate Analytics) for journal articles published between January 1995 and 10th November 2020 was conducted. Articles assessing nutraceutical interventions and ME/CFS patient outcomes were retrieved. Using specific inclusion and exclusion criteria, the list of articles was further refined. Quality was measured using the Rosendal scale.

Results
Nine intervention studies were included in this review. The studies investigated patient symptom severity changes such as altered fatigue levels in response to mitochondrial-targeting nutraceuticals. Improvements in fatigue levels were observed in six of the nine studies. Secondary outcomes assessed include biochemical, psychological, and quality of life parameters.

Conclusion
There is insufficient evidence on the effectiveness of mitochondria- targeting nutraceuticals in ME/CFS patients. Future well-designed studies are required to elucidate both the involvement of mitochondria in the pathomechanism of ME/CFS and the effect of mitochondrial-modifying agents on illness severity.
Click to expand...

https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-021-02742-4
 
Tom Kindlon said:
Not picked up by the algorithm:
"Amantadine & L-carnitine treatment of #ChronicFatigueSyndrome" https://pubmed.ncbi.nlm.nih.gov/9018019/
This used 3000 mg of L-carnitine (a lot of people who try it don't take that dosage)
This has helped me: particularly noticeable when I stopped it
Click to expand...
Yes, L Carnitine is very interesting; I do not haveME, but I use 3000-4000mg per day to deal with being in the grey zone on the edge of moving to hyperthyroid. Many years ago an Italian endocrinologist used this method, along with an occasional Ativan 1mg, to deal with folks in the grey zone. I have been doing this for 10 years. But in the case of ME, if there is low thyroid using L carnitine would be a very risky business.
 
You must log in or register to reply here.
Back
Top Bottom